Print

Teva Women's Health, Inc. (TEVA) Announces New Data on Phase III Investigational Progesterone Vaginal Ring at the 68th Annual Meeting of the American Society for Reproductive Medicine  
10/23/2012 9:27:46 AM

FRAZER, Pa.--(BUSINESS WIRE)--Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced findings from a Phase III clinical trial of MilprosaTM (progesterone), an investigational weekly progesterone vaginal ring for luteal supplementation in women undergoing in vitro fertilization (IVF). These data were presented as an oral presentation at the 68th Annual Meeting of the American Society for Reproductive Medicine (ASRM).
//-->